Rankings
▼
Calendar
AKBA Q3 2024 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AKBA
Akebia Therapeutics, Inc.
$365M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$37M
-11.0% YoY
Gross Profit
$23M
62.2% margin
Operating Income
-$13M
-33.4% margin
Net Income
-$20M
-53.5% margin
EPS (Diluted)
$-0.10
QoQ Revenue Growth
-14.3%
Cash Flow
Operating Cash Flow
-$7M
Free Cash Flow
-$7M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$207M
Total Liabilities
$258M
Stockholders' Equity
-$50M
Cash & Equivalents
$34M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$37M
$42M
-11.0%
Gross Profit
$23M
$24M
-3.2%
Operating Income
-$13M
-$13M
+4.1%
Net Income
-$20M
-$14M
-38.3%
Revenue Segments
Product
$36M
95%
License Collaboration And Other Revenue
$2M
5%
← FY 2024
All Quarters
Q4 2024 →